|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 100 DAINGERFIELD ROAD |
Address2 | 3rd FLOOR |
City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Alexandria |
State | VA |
Zip Code | 22314 |
Country | USA |
|
5. Senate ID# 27478-12
|
||||||||
|
6. House ID# 303540000
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Steve Pfister |
Date | 10/14/2016 9:25:27 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 244 - MAC Transparency Act of 2015;
Congressional Oversight of 340 B Program;
S. 1406 - Saving Access to Compounding Medications for Special Needs Patients Act;
Issues related to FDA implementation of The Drug Quality and Security Act related to compounding;
Issues Related to Direct and Indirect Renumeration (DIR) Fees;
H.R. 5951/S. 3308 - Improving Transparency and Accuracy in Medicare Part D Spending Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Government Accountability Office (GAO), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
LaViolette |
|
|
|
Steve |
Pfister |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Ronna |
Hauser |
|
|
|
Matthew |
DiLoreto |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
H.R. 471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015;
S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015;
Implementation of Public Law 114-198;
S.524 - Comprehensive Addiction and Recovery Act of 2016;
H.R.953 - Comprehensive Addiction and Recovery Act of 2015;
H.R. 3250 - DXM Abuse Prevention Act;
H.R. 5951/S. 3308 - Improving Transparency and Accuracy in Medicare Part D Spending Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Office of Natl Drug Control Policy (NDCP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
LaViolette |
|
|
|
Steve |
Pfister |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Matthew |
DiLoreto |
|
|
|
Ronna |
Hauser |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S. 776 - Medication Therapy Empowerment Act of 2015;
H.R. 1021 - Protecting the Management Integrity of Medicare Act of 2015;
H.R. 1270 - Restoring Access to Medication Act of 2015;
S. 709- Restoring Access to Medication Act of 2015;
H.R. 2- Medicare Access and Chip Reauthorization Act of 2015;
H.R. 793 - Ensuring Seniors Access to Local Pharmacies Act of 2015;
S. 1190 -Ensuring Seniors Access to Local Pharmacies Act of 2015;
S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act;
H.R. 592 - Pharmacy and Medically Underserved Areas Enhancement Act;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Personnel Management (OPM), Office of Management & Budget (OMB), Government Accountability Office (GAO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
LaViolette |
|
|
|
Susan |
Pilch |
|
|
|
Steve |
Pfister |
|
|
|
Michael |
Tomberlin |
|
|
|
Matthew |
DiLoreto |
|
|
|
Ronna |
Hauser |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
TRICARE Pharmacy Benefit Provisions;
National Defense Authorization Act H.R. 4909 - National Defense Authorization Act;
S. 2943 - National Defense Authorization Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
LaViolette |
|
|
|
Susan |
Pilch |
|
|
|
Steve |
Pfister |
|
|
|
Michael |
Tomberlin |
|
|
|
Matthew |
DiLoreto |
|
|
|
Ronna |
Hauser |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Small Business Tax Reform
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
LaViolette |
|
|
|
Steve |
Pfister |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Matthew |
DiLoreto |
|
|
|
Ronna |
Hauser |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 6 - 21st Century Cures Act;
Senate HELP Innovation Initiative: How to Get Medical Devices, Drugs, Treatments From Discovery to the Medicine Cabinet
S. 1913 - Stopping Medication Abuse and Protecting Seniors Act of 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
LaViolette |
|
|
|
Steve |
Pfister |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Matthew |
DiLoreto |
|
|
|
Ronna |
Hauser |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Issues related to compounded pharmaceuticals for animals;
S. 1200 - Fairness to Pet Owners Act 2015;
H.R. 3174 - Fairness to Pet Owners Act of 2015;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Steve |
Pfister |
|
|
|
Karry |
LaViolette |
|
|
|
Mike |
Tomberlin |
|
|
|
Susan |
Pilch |
|
|
|
Matthew |
DiLoreto |
|
|
|
Ronna |
Hauser |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act;
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, specifically FDA funding for implementation of the Drug Quality and Security Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Steve |
Pfister |
|
|
|
Karry |
LaViolette |
|
|
|
Mike |
Tomberlin |
|
|
|
Susan |
Pilch |
|
|
|
Matthew |
DiLoreto |
|
|
|
Ronna |
Hauser |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |